LIVIVO - Search results -

Search results

Result 1 - 10 of total 29

Search options

Article: Dosing of biologics in juvenile idiopathic arthritis: is the sky the limit?

Prince, Femke H M / Solomon, Daniel H

2013 Volume 40, Issue 10, Page(s) 1643–1645

MeSH term(s)	Antibodies, Monoclonal/therapeutic use ; Antirheumatic Agents/therapeutic use ; Arthritis, Juvenile/drug therapy ; Female ; Humans ; Infliximab ; Male
Chemical Substances	Antibodies, Monoclonal ; Antirheumatic Agents ; Infliximab (B72HH48FLU)
Language	English
Publishing date	2013-10
Publishing country	Canada
Document type	Comment ; Editorial
ZDB-ID	194928-7
ISSN	1499-2752 ; 0315-162X
ISSN (online)	1499-2752
ISSN	0315-162X
DOI	10.3899/jrheum.130875
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1168: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 135: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Correction: Prevalence and predictors for sustained remission in rheumatoid arthritis.

Sung, Yoon-Kyoung / Yoshida, Kazuki / Prince, Femke H M / Frits, Michelle L / Cho, Soo-Kyung / Choe, Jung-Yoon / Lee, Hye-Soon / Lee, Jisoo / Lee, Shin-Seok / Yoo, Dae-Hyun / Helfgott, Simon M / Shadick, Nancy A / Weinblatt, Michael E / Solomon, Daniel H / Bae, Sang-Cheol

PloS one

2019 Volume 14, Issue 8, Page(s) e0221314

Abstract: This corrects the article DOI: 10.1371/journal.pone.0214981.]. ...

Abstract	[This corrects the article DOI: 10.1371/journal.pone.0214981.].
Language	English
Publishing date	2019-08-14
Publishing country	United States
Document type	Published Erratum
ISSN	1932-6203
ISSN (online)	1932-6203
DOI	10.1371/journal.pone.0221314
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked.

Prince, Femke H M / van Suijlekom-Smit, Lisette W A

Paediatric drugs

2013 Volume 15, Issue 4, Page(s) 271–280

Abstract: Biologics are a promising treatment option for juvenile idiopathic arthritis (JIA) but drug costs are very high compared to conventional treatment. From a socioeconomic view the additional costs of new interventions should be weighed against their ... ...

Abstract	Biologics are a promising treatment option for juvenile idiopathic arthritis (JIA) but drug costs are very high compared to conventional treatment. From a socioeconomic view the additional costs of new interventions should be weighed against their incremental health benefits compared to standard care. Therefore we evaluated data on cost-effectiveness of biologics in JIA. We searched Medline, Embase, and The York Centre for Reviews and Dissemination database for relevant literature. Current data show that biologics are reducing direct and indirect healthcare costs if one excludes the costs of the drug itself. The costs of biologics are more than ten times as high as conventional drug treatment. As a result of limited data, no comparison on cost-effectiveness between biologics could be performed. Although data on long-term cost-effectiveness of biologics are lacking, the expectation is that they will be cost-effective in the long-term. The idea behind this is that biologic treatment should be administered to patients that without these drugs would incur high direct and indirect costs due to continuous severe disease resulting in irreversible disabilities. In our opinion the best cost benefit could be gained if these patients receive biologic treatment introduced early in the disease. This is in order to minimize irreversible damage to the joints and minimize need for long-term biologic therapy by early suppression of the disease. To support these hypotheses future research is needed on long-term cost-effectiveness of all biologics used in JIA.
MeSH term(s)	Arthritis, Juvenile/drug therapy ; Arthritis, Juvenile/economics ; Biological Products/economics ; Biological Products/therapeutic use ; Cost-Benefit Analysis ; Drug Costs ; Humans
Chemical Substances	Biological Products
Language	English
Publishing date	2013-04-21
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	1492748-2
ISSN	1179-2019 ; 1174-5878
ISSN (online)	1179-2019
ISSN	1174-5878
DOI	10.1007/s40272-013-0023-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5205: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Correction

Yoon-Kyoung Sung / Kazuki Yoshida / Femke H M Prince / Michelle L Frits / Soo-Kyung Cho / Jung-Yoon Choe / Hye-Soon Lee / Jisoo Lee / Shin-Seok Lee / Dae-Hyun Yoo / Simon M Helfgott / Nancy A Shadick / Michael E Weinblatt / Daniel H Solomon / Sang-Cheol Bae

PLoS ONE, Vol 14, Iss 8, p e

Prevalence and predictors for sustained remission in rheumatoid arthritis.

2019 Volume 0221314

Abstract: This corrects the article DOI:10.1371/journal.pone.0214981.]. ...

Abstract	[This corrects the article DOI:10.1371/journal.pone.0214981.].
Keywords	Medicine ; R ; Science ; Q
Language	English
Publishing date	2019-01-01T00:00:00Z
Publisher	Public Library of Science (PLoS)
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Prevalence and predictors for sustained remission in rheumatoid arthritis.

PloS one

2019 Volume 14, Issue 4, Page(s) e0214981

Abstract: Objective: Remission is a key goal in managing rheumatoid arthritis (RA), with sustained remission as the preferred sequelae of short-term remission. However little is known about the predictors of sustained remission for patients reaching remission. ... ...

Abstract	Objective: Remission is a key goal in managing rheumatoid arthritis (RA), with sustained remission as the preferred sequelae of short-term remission. However little is known about the predictors of sustained remission for patients reaching remission. Using two independent cohorts, we aimed to evaluate the prevalence and predictors for sustained remission. Methods: The study cohort consisted of subjects with RA from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS) and the Korean Observational Study Network for Arthritis (KORONA). We analyzed subjects who reached remission in 2009 with follow up data for two consecutive years. Remission was defined by the Disease Activity Score 28- (DAS28-CRP) of less than 2.6. Sustained remission was defined as three consecutive annual visits in remission. Predictors for sustained remission were identified by multivariate logistic regression analysis. Results: A total of 465 subjects were in remission in 2009. Sustained remission was achieved by 53 of 92 (57.5%) in BRASS and by 198 of 373 (53.1%) in KORONA. In multivariate analyses, baseline predictors of sustained remission were: disease duration less than 5 years [odds ratio (OR) 1.96, 95% confidence interval (95% CI) 1.08-3.58], Modified Health Assessment Questionnaire (MHAQ) score of 0 (OR 1.80, 95% CI 1.18-2.74), and non-use of oral glucocorticoid (OR 1.58, 95% CI 1.01-2.47). Conclusion: More than half of RA subjects in remission in 2009 remained in remission through 2011. Short disease duration, no disability, and non-use of oral glucocorticoid at baseline were associated with sustained remission.
MeSH term(s)	Aged ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/epidemiology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Prevalence ; Prospective Studies ; Remission Induction ; Republic of Korea/epidemiology
Language	English
Publishing date	2019-04-19
Publishing country	United States
Document type	Clinical Trial ; Journal Article ; Multicenter Study ; Observational Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ISSN	1932-6203
ISSN (online)	1932-6203
DOI	10.1371/journal.pone.0214981
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Initiating etanercept in a once weekly dose in children with juvenile idiopathic arthritis.

Prince, Femke H M / van Suijlekom-Smit, Lisette W A

Rheumatology international

2007 Volume 28, Issue 4, Page(s) 397–8, author reply 399

MeSH term(s)	Adolescent ; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage ; Arthritis, Juvenile/drug therapy ; Child ; Drug Administration Schedule ; Drug Therapy, Combination ; Etanercept ; Female ; Glucocorticoids/administration & dosage ; Humans ; Immunoglobulin G/administration & dosage ; Immunoglobulin G/adverse effects ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/adverse effects ; Male ; Methotrexate/administration & dosage ; Prednisone/administration & dosage ; Receptors, Tumor Necrosis Factor/administration & dosage ; Treatment Outcome
Chemical Substances	Anti-Inflammatory Agents, Non-Steroidal ; Glucocorticoids ; Immunoglobulin G ; Immunosuppressive Agents ; Receptors, Tumor Necrosis Factor ; Etanercept (OP401G7OJC) ; Prednisone (VB0R961HZT) ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2007-10-17
Publishing country	Germany
Document type	Comment ; Letter
ZDB-ID	8286-7
ISSN	1437-160X ; 0172-8172
ISSN (online)	1437-160X
ISSN	0172-8172
DOI	10.1007/s00296-007-0468-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1639: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Veneuze trombose als eerste signaal van SLE.

Pronk, Suzanne M / van Ommen, C Heleen / Prince, Femke H M / Weijer, Olivier / van Rossum, Marion A J

Nederlands tijdschrift voor geneeskunde

2014 Volume 158, Page(s) A7179

Abstract: Background: Venous thrombosis in children is rare. In adolescents it may be the first manifestation of a chronic disease such as systemic lupus erythematosus (SLE).: Case description: An obese 12-year-old girl visited the Obesity Clinic and mentioned ...

Title translation	Venous thrombosis as a first sign of SLE.
Abstract	Background: Venous thrombosis in children is rare. In adolescents it may be the first manifestation of a chronic disease such as systemic lupus erythematosus (SLE). Case description: An obese 12-year-old girl visited the Obesity Clinic and mentioned pain in her right calf. Some time before her arrival she spent time in bed with a respiratory infection. Deep vein thrombosis was diagnosed by ultrasonography. Radiography showed an infiltrate, laboratory tests showed elevated inflammatory parameters, and thrombophilia testing showed a Factor V Leiden mutation as well as the presence of lupus anticoagulants. During her stay she developed haematological, immunological and clinical signs of SLE. Conclusion: The cause of venous thrombosis in children is usually multifactorial. Despite the presence of obvious risk factors, it is important to follow adolescents with thrombosis and to be alert for any signs of an underlying systemic disease.
MeSH term(s)	Adolescent ; Factor V/genetics ; Female ; Humans ; Lupus Erythematosus, Systemic/complications ; Lupus Erythematosus, Systemic/diagnosis ; Risk Factors ; Venous Thrombosis/etiology
Chemical Substances	factor V Leiden ; Factor V (9001-24-5)
Language	Dutch
Publishing date	2014
Publishing country	Netherlands
Document type	Case Reports ; English Abstract ; Journal Article
ZDB-ID	82073-8
ISSN	1876-8784 ; 0028-2162
ISSN (online)	1876-8784
ISSN	0028-2162
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.18: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Diagnosis and management of juvenile idiopathic arthritis.

Prince, Femke H M / Otten, Marieke H / van Suijlekom-Smit, Lisette W A

BMJ (Clinical research ed.)

2010 Volume 341, Page(s) c6434

MeSH term(s)	Adrenal Cortex Hormones/therapeutic use ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Antirheumatic Agents/therapeutic use ; Arthritis, Juvenile/diagnosis ; Arthritis, Juvenile/therapy ; Diagnosis, Differential ; Early Diagnosis ; Humans ; Medical History Taking/methods ; Physical Examination/methods ; Referral and Consultation
Chemical Substances	Adrenal Cortex Hormones ; Anti-Inflammatory Agents, Non-Steroidal ; Antirheumatic Agents
Language	English
Publishing date	2010-12-03
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1362901-3
ISSN	1756-1833 ; 0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
ISSN (online)	1756-1833
ISSN	0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
DOI	10.1136/bmj.c6434
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.

Gohar, Faekah / Anink, Janneke / Moncrieffe, Halima / Van Suijlekom-Smit, Lisette W A / Prince, Femke H M / van Rossum, Marion A J / Dolman, Koert M / Hoppenreijs, Esther P A H / Ten Cate, Rebecca / Ursu, Simona / Wedderburn, Lucy R / Horneff, Gerd / Frosch, Michael / Foell, Dirk / Holzinger, Dirk

The Journal of rheumatology

2018 Volume 45, Issue 4, Page(s) 547–554

Abstract: Objective: Around one-third of patients with juvenile idiopathic arthritis (JIA) fail to respond to first-line methotrexate (MTX) or anti-tumor necrosis factor (TNF) therapy, with even fewer achieving ≥ American College of Rheumatology Pediatric 70% ... ...

Abstract	Objective: Around one-third of patients with juvenile idiopathic arthritis (JIA) fail to respond to first-line methotrexate (MTX) or anti-tumor necrosis factor (TNF) therapy, with even fewer achieving ≥ American College of Rheumatology Pediatric 70% criteria for response (ACRpedi70), though individual responses cannot yet be accurately predicted. Because change in serum S100-protein myeloid-related protein complex 8/14 (MRP8/14) is associated with therapeutic response, we tested granulocyte-specific S100-protein S100A12 as a potential biomarker for treatment response. Methods: S100A12 serum concentration was determined by ELISA in patients treated with MTX (n = 75) and anti-TNF (n = 88) at baseline and followup. Treatment response (≥ ACRpedi50 score), achievement of inactive disease, and improvement in Juvenile Arthritis Disease Activity Score (JADAS)-10 score were recorded. Results: Baseline S100A12 concentration was measured in patients treated with anti-TNF [etanercept n = 81, adalimumab n = 7; median 200, interquartile range (IQR) 133-440 ng/ml] and MTX (median 220, IQR 100-440 ng/ml). Of the patients in the anti-TNF therapy group, 74 (84%) were also receiving MTX. Responders to MTX (n = 57/75) and anti-TNF (n = 66/88) therapy had higher baseline S100A12 concentration compared to nonresponders: median 240 (IQR 125-615) ng/ml versus 150 (IQR 87-233) ng/ml, p = 0.021 for MTX, and median 308 (IQR 150-624) ng/ml versus 151 (IQR 83-201) ng/ml, p = 0.002, for anti-TNF therapy. Followup S100A12 could be measured in 44/75 MTX-treated patients (34/44 responders) and 39/88 anti-TNF-treated patients (26/39 responders). Responders had significantly reduced S100A12 concentration (MTX: p = 0.031, anti-TNF: p < 0.001) at followup versus baseline. Baseline serum S100A12 in both univariate and multivariate regression models for anti-TNF therapy and univariate analysis alone for MTX therapy was significantly associated with change in JADAS-10. Conclusion: Responders to MTX or anti-TNF treatment can be identified by higher pretreatment S100A12 serum concentration levels.
MeSH term(s)	Adolescent ; Antirheumatic Agents/pharmacology ; Antirheumatic Agents/therapeutic use ; Arthritis, Juvenile/blood ; Arthritis, Juvenile/drug therapy ; Biomarkers/blood ; Child ; Child, Preschool ; Female ; Follow-Up Studies ; Humans ; Linear Models ; Logistic Models ; Male ; Methotrexate/therapeutic use ; Multivariate Analysis ; S100A12 Protein/blood ; Statistics, Nonparametric ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
Chemical Substances	Antirheumatic Agents ; Biomarkers ; S100A12 Protein ; S100A12 protein, human ; Tumor Necrosis Factor-alpha ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2018-01-15
Publishing country	Canada
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	194928-7
ISSN	1499-2752 ; 0315-162X
ISSN (online)	1499-2752
ISSN	0315-162X
DOI	10.3899/jrheum.170438
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1168: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 135: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Prevalence and predictors for sustained remission in rheumatoid arthritis.

PLoS ONE, Vol 14, Iss 4, p e

2019 Volume 0214981

Abstract: Objective Remission is a key goal in managing rheumatoid arthritis (RA), with sustained remission as the preferred sequelae of short-term remission. However little is known about the predictors of sustained remission for patients reaching remission. ... ...

Abstract	Objective Remission is a key goal in managing rheumatoid arthritis (RA), with sustained remission as the preferred sequelae of short-term remission. However little is known about the predictors of sustained remission for patients reaching remission. Using two independent cohorts, we aimed to evaluate the prevalence and predictors for sustained remission. Methods The study cohort consisted of subjects with RA from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS) and the Korean Observational Study Network for Arthritis (KORONA). We analyzed subjects who reached remission in 2009 with follow up data for two consecutive years. Remission was defined by the Disease Activity Score 28- (DAS28-CRP) of less than 2.6. Sustained remission was defined as three consecutive annual visits in remission. Predictors for sustained remission were identified by multivariate logistic regression analysis. Results A total of 465 subjects were in remission in 2009. Sustained remission was achieved by 53 of 92 (57.5%) in BRASS and by 198 of 373 (53.1%) in KORONA. In multivariate analyses, baseline predictors of sustained remission were: disease duration less than 5 years [odds ratio (OR) 1.96, 95% confidence interval (95% CI) 1.08-3.58], Modified Health Assessment Questionnaire (MHAQ) score of 0 (OR 1.80, 95% CI 1.18-2.74), and non-use of oral glucocorticoid (OR 1.58, 95% CI 1.01-2.47). Conclusion More than half of RA subjects in remission in 2009 remained in remission through 2011. Short disease duration, no disability, and non-use of oral glucocorticoid at baseline were associated with sustained remission.
Keywords	Medicine ; R ; Science ; Q
Subject code	500
Language	English
Publishing date	2019-01-01T00:00:00Z
Publisher	Public Library of Science (PLoS)
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED